Last reviewed · How we verify
Ganeden BC30
Ganeden BC30 is a probiotic strain of Bacillus coagulans that promotes gastrointestinal health by producing lactic acid and supporting beneficial gut microbiota.
Ganeden BC30 is a probiotic strain of Bacillus coagulans that promotes gastrointestinal health by producing lactic acid and supporting beneficial gut microbiota. Used for Digestive health and gastrointestinal support, Occasional digestive discomfort.
At a glance
| Generic name | Ganeden BC30 |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
BC30 is a spore-forming probiotic bacterium that survives stomach acid and colonizes the small intestine, where it produces lactic acid to create an acidic environment that inhibits pathogenic bacteria growth. It also supports the natural gut microbiota balance and may enhance intestinal barrier function and immune response through interaction with gut-associated lymphoid tissue.
Approved indications
- Digestive health and gastrointestinal support
- Occasional digestive discomfort
Common side effects
- Mild gastrointestinal symptoms (bloating, gas)
- Transient digestive changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ganeden BC30 CI brief — competitive landscape report
- Ganeden BC30 updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI